Singular changes the way biopharma industry approaches the rare disease landscape in Europe. We identify actual cases benefitting from your orphan drug. No matter how rare it is. We provide solid competitive strategies and tailored business development methodology that anticipates revenue generation. Singular offers bespoke consulting services to biopharmaceutical companies willing to enter the European market: • Rare Disease Case Identification • KOL identification • Business Model and business Strategy design & analysis • Route-to-Market plans • Competitive Strategies